Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

46 results
Display

HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases

Li YJ, Li JW, Chen KL, Li J, Zhong MZ, Liu XL, Yi PY, Zhou H

BACKGROUND: Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma (PBL) is a rare entity of diffuse large B-cell lymphoma (DLBCL). The clinicopathological features of and optimal treatment for HIV-negative PBL remain largely...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Necrobiotic Xanthogranuloma Coexists with Diffuse Normolipidemic Plane Xanthoma and Multiple Myeloma

Kim JG, Kim HR, You MH, Shin DH, Choi JS, Bae YK

Necrobiotic xanthogranuloma (NXG), is a rare multisystem disease that manifests as cutaneous inflammatory lesions, and is commonly associated with lymphoproliferative disease. Diffuse normolipemic plane xanthoma (NX), is also a rare,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Lenalidomide-induced Drug Eruption Presenting as Pruritus and Erythema Covering the Whole Body

Shin JY, Hong KR, Kim JE, Lee SH, Park YL

  • KMID: 2446922
  • Korean J Dermatol.
  • 2019 Mar;57(3):149-151.
Lenalidomide is an immunomodulatory drug used for the treatment of multiple myeloma. Several cases of hematological, gastrointestinal, and cutaneous side effects have been reported for this drug. A 67-year-old patient...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Successful treatment of early acute antibody-mediated rejection in an human leukocyte antigen-incompatible and ABO-incompatible living-donor kidney transplant patient

Gang S, Han A, Min SI, Ha J, Yang J

For successful human leukocyte antigen-incompatible (HLAi) or ABO-incompatible (ABOi) living-donor kidney transplantations (LDKTs), pretransplant desensitization is essential; however, early antibody-mediated rejection (ABMR) remains the most important complication after HLAi or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

Lee SR, Choi H, Lee BH, Kang KW, Yu ES, Kim DS, Park Y, Choi CW, Kim BS, Sung HJ

BACKGROUND/AIMS: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Amyloidosis Presenting as Lymphadenopathy at the Porta Hepatis

Lee JI, Kim JS, Kim BW

We report a rare case of systemic amyloidosis with gastrointestinal and lymph node involvement. A 64-year-old woman was admitted to our hospital with dyspepsia and weight loss. Initial esophagogastroduodenoscopy (EGD)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib Treatment for Refractory Antibody-Mediated Rejection Superimposed with BK Virus-Associated Nephropathy during the Progression of Recurrent C3 Glomerulonephritis

Do W, Lee JH, Kim KJ, Han MH, Jung HY, Choi JY, Park SH, Kim YL, Kim CD, Cho JH, Yang Y, Kim M, Hwang I, Kim KY, Yim T, Kim YJ

A 38-year-old man, who underwent a second kidney transplantation (KT), was admitted because of antibody-mediated rejection (AMR) complicated by BK virus-associated nephropathy (BKVAN). He was placed on hemodialysis at the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation

Kim SJ, Jun KW, Hwang JK, Chung BH, Yang CW, Moon IS, Kim JI, Kim MH

BACKGROUND: Bortezomib has been used to treat antibody-mediated rejection (AMR) that usually develops after kidney transplantation (KT). Although it has been used in various clinical situations, it is difficult to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia

Yap YY, Sathar J, Law KB, Zulkurnain PAB, Edmund SC, Chang KM, Baker R

BACKGROUND: Thrombotic microangiopathy (TMA) with non-deficient ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13) outcome is unknown hence the survival analysis correlating with ADAMTS-13 activity is conducted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Inhibition of the 26S and 20S Proteasomes by the Site-specific Inhibitors

Woo KM

OBJECTIVE: The study was performed to establish the purification processes of both 26S and 20S proteasomes, also to investigate the inhibitory properties and patterns of two different proteasome inhibitors on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen

Cho HJ, Seo SK, Baek DW, Park SW, Lee YJ, Sohn SK, Lee HS, Lee WS, Lee JH, Kim SH, Moon JH

BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis

Lee DM, Kim IY, Seo MJ, Kwon MR, Choi KS

The proteasome inhibitor, bortezomib, is ineffective against many solid tumors. Nutlin-3 is a potent antagonist of human homolog of murine double minute 2/p53 interaction exhibiting promising therapeutic anti-cancer activity. In...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party

Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK, Korean Multiple Myeloma Working Party

BACKGROUND: Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. METHODS: We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients

Lee SS, Jung SH, Ahn JS, Kim YK, Cho MS, Jung SY, Lee JJ, Kim HJ, Yang DH

Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens

Hyun SY, Han SH, Kim SJ, Jang JE, Kim Y, Cho H, Lee JY, Cheong JW, Min YH, Song JW, Kim JS

The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens. A total of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib-induced Histiocytoid Sweet Syndrome

Oh YJ, Lew BL, Sim WY

  • KMID: 2359680
  • Korean J Dermatol.
  • 2016 Nov;54(9):739-743.
Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Progression of Extramedullary Plasmacytoma in a Multiple Myeloma Patient with No Increment in Serum M Protein Level

Kim SH, Jee YG, Yeo WH, Sohn BS, Kim SR, Kim HJ, Yuh YJ

A 76 year-old female who was diagnosed with multiple myeloma (IgG, lambda) had received bortezomib, melphalan and prednisolone as first-line treatment. After completing six cycles of chemotherapy, her serum monoclonal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Bortezomib-induced Drug Eruption Presenting as Multiple Plaques on the Trunk

Choe YS, Kim EJ, Na JI

  • KMID: 2245828
  • Korean J Dermatol.
  • 2016 Jan;54(1):47-51.
Bortezomib (Velcade(R)) is proteasome inhibitor that is used as a first-line therapy for multiple myeloma. It can cause gastrointestinal, hematologic, and neuromuscular side effects, and a cutaneous reaction is one...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma

Lim JH, Hwang KB, Lim BH, Jeong YH, Sohn KC, Kim TH

Bortezomib is a proteasome inhibitor used for the treatment of patients with multiple myeloma. Recently, several case reports about acute pancreatitis caused by Bortezomib were published in the international literature....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib inhibits the survival and proliferation of bone marrow stromal cells

Kim HY, Moon JY, Ryu H, Choi YS, Song IC, Lee HJ, Yun HJ, Kim S, Jo DY

BACKGROUND: Bortezomib is widely used for the treatment of multiple myeloma. Bone marrow stromal cells (BMSCs) endow myeloma cells with survival and growth advantages. However, the influence of bortezomib on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr